← FDA DRUG APPROVALS

FDA ANDA · ANDA040279

FLUOROURACIL

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA040279
TYPE
ANDA
ORIGINAL APPROVAL
1998-09-30
LATEST ACTION
2026-02-05
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

FLUOROURACILPrescription
FLUOROURACIL 500MG/10ML (50MG/ML) · INJECTABLE · INJECTION
FLUOROURACILPrescription
FLUOROURACIL 1GM/20ML (50MG/ML) · INJECTABLE · INJECTION

Approval history

2026-02-05Labeling · Supplement 32 · standardLabelAP
2024-03-21Labeling · Supplement 30 · standardLetterAP
2017-01-06Labeling · Supplement 19 · standardAP
2002-12-05Manufacturing (CMC) · Supplement 3AP
1999-07-06Manufacturing (CMC) · Supplement 1AP
1998-09-30OriginalLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →